Identification Of Protein Biomarkers In Bronchoalveolar Lavage (BAL) Fluid To Improve The Detection Of Lung Cancer From Benign Lung Nodule | 16437
Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Recent clinical screening trials using highly sensitive low-dose computed tomography (LDCT) demonstrated an improved
overall survival of lung cancer patients. However, these trials showed high repeat screening rates and high false-positive
rates causing unnecessary second-line invasive procedures and surgery. New strategies are needed to improve the specificity
of lung cancer screening. Bronchoalveolar lavage (BAL) is commonly used for the cytological evaluation of cells in lung
nodules and diagnosis of lung cancers, proteins in the BAL fluid not examined in clinical practice, might serve as biomarkers
for cancer diagnosis. We collected sixteen BAL samples, including four cases each of benign lung disease, adenocarcinoma
(ADC), squamous cell carcinoma (SqCC), and small cell carcinoma (SCLC), and studied protein profiles using the solid-phase
extraction of N-glycoprotein (SPEG) and liquid chromatography tandem mass spectrometry (LC-MS/MS). A total of 1013
unique peptides from 457 glycoproteins were identified and quatified. Among them, 286 proteins were identified in BAL of
ADC, 363 in squamous cell carcinoma (SqCC), 298 in SCLC and 330 in benign BALs. In addition to common proteins found
in all groups, we identified 113 unique proteins that were differentially expresssed exclusively in either benign disease, ADC,
SqCC or SCLC. The levels of four proteins in cancer and benign BALs were further validated using independently collected 117
BAL specimens by ELISA assays. Our study demonstrates that proteins in BAL fluid have the potential to be used as biomarkers
to improve the specificity of lung screening tests and the early detection of lung cancers.
Qing Kay Li is an American Board of Pathology certified pathologist and an Associate Professor of the Department of Pathology at the Johns Hopkins Medical
Institutions. In addition to clinical service, her research effort is focused on the early detection of lung and prostate cancers. She has published more than 50 papers
in peer-reviewed journals and served in study sections for reviewing grant applications. She also serves as editorial board member of journals and committee
member of the American Society of Cytopathology.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals